Skip to main content

Tweets

Race to the top: how high will treatment response rates in RA reach? We have become used to the 60/40/20% rule for the outcome of ACR 20/50/70 for biologics and targeted synthetic DMARDs. https://t.co/VJplM5GC31 https://t.co/gNsN3wX5tA
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
2023 EULAR #PMR referral recommendations: 1 Suspected/Dx pts: consider Rheum eval 2 Do full Hx+PE+Labs before referral 3 Refer Severe Sx PMR to rapid access 4 Defer steroids til rapid Rheum eval 5 Rheum Dx PMR w? +steroid response can be Rx by PCP https://t.co/42bL8BL3QJ https://t.co/ffpKoKXZJM
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Withdraw DMARDS after remission? Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer. https://t.co/mQKhwv9wCt https://t.co/Q57t63vNKe
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Calcineurin Inhibitors in Lupus Nephritis Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/4CjJ8Ri3ym https://t.co/KUONVdMfBB
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
How do we Diversify Clinical Trials? Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/fZ7kKfdRwP https://t.co/Non3X7zOxA
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Is MTX Safe in the Elderly? Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adult rheumatology positions matched! But 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled. https://t.co/un9CbyYooL https://t.co/ilABvgr7bH
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Pneumocystis Jiroveci Pneumonia (PJP) Risk https://t.co/6kP3IjmHi1 https://t.co/ERwIeTKBYp
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
resolved HBV (HBsAg-, HBcAb+, HBsAb+) are at low risk of reactivation (~2%) w/ TNFi or biologics. But in a high risk endemic region (ie, Korea) this risk is higher. Study of 416 such pts HBV reactivation rate 3.5% @5 yrs, 6.1% @10 yrs & 24.2% @17 yrs https://t.co/oQ5e6O9wds https://t.co/50vBtapJVN
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Risk of Hepatitis B reactivation is assessed by serology - Resolved HBV (low risk reactiv): HBsAg-neg, HBcAb–pos & Pos HBsAb - If HBcAb(+), HBsAb negativity incr risk; - HBsAg(-), HBcAb(+), HBsAb(-) negative= resolved infx, occult infx, chronic hepatitis https://t.co/91ZwqWkdvo https://t.co/c23nN8ER1Y
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
#RA pattern of synovitis is well knownn & decr in grip strength seen in Early (39%) & later RA (59% @5y). MCP1 synovitis impacts grip strength most (60%) followed by MCP4 (much less w/ tender/swelling of PIPs,other MCPs). Based on study of 215 early RA pts https://t.co/rTFBHKlNGV https://t.co/zCVsTNuYWW
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
ARCTIC Rewind: Three-Year Data in RA https://t.co/ls2e3LtlvK https://t.co/FtgSq713rc
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
Rheum Fellowship Slots Fill Up for 2024 The NRMP announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions. https://t.co/wTwajHyal0 https://t.co/JpgDUmioQh
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
×